JPRN-jRCT2031210239进行中（未招募）1 期
A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2alpha stabilizing mutations
Yonemura Masataka0 个研究点目标入组 180 人开始时间: 2021年8月13日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •For dose escalation and expansion arms on SA and combos, with the exception of Arm1B:
- •1. Male and female >= 18 years of age
- •2. Histologically confirmed and documented clear cell renal cell carcinoma (ccRCC). Disease must be measureable as determined by RECIST v1.1.
- •3. Patient with unresectable, locally advanced or metastatic ccRCC with documented disease progression following therapy with PD-1/L1 checkpoint inhibitor and a VEGF targeted therapy as monotherapy or in combination.
- •Escalation: No restriction on the number of prior treatments
- •Expansion: Up to 3 prior lines of treatment for advanced/metastatic disease
- •4. ECOG performance status =<1
- •For basket arm (Arm 1B):
- •1. Male and female of age >= 12 years of age.
- •2. Histologically confirmed and documented malignancies in the context of the following cancer predisposing syndromes/disorders or harboring somatic mutations on one of these genes:
- •- Malignancies with VHL mutations (e.g. Von Hippel-Lindau disease)
- •- Malignancies with FH mutations (e.g. Hereditary leiomyomatosis and renal cell carcinoma)
- •- Malignancies with mutations in SDHD, SDHAF2, SDHC, SDHB, SDHA (e.g. Hereditary paraganglioma and pheochromocytoma syndrome)
- •- Malignancies with EPAS1/HIF2A mutations
- •- Malignancies with ELOC/TCEB1 mutations
- •3. Patients must have either metastatic disease or locally advanced disease that is unresectable or that patients be unfit for resection or other treatment modalities. Patients must have received prior standard therapy appropriate for their tumor type and stage of disease, and have no available therapies of proven clinical benefit; or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy.
- •4. For patients age >= 16 years: ECOG performance status =< 1
- •For patients age >= 12 and < 16 years: Lansky performance status >= 70
排除标准
- •1. Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but limited to surgery, radiation and/or corticosteroids. Patients with treated symptomatic brain metastases should be neurologically stable for 4 weeks post-treatment prior to study entry and at doses =< 10 mg per day prednisone or equivalent for at least 2 weeks before administration of any study treatment.
- •2. History of seizure disorder and/or extrapyramidal symptoms.
- •3. Known additional malignancy that is progressing or requires active treatment within the past 3 year(s). Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or other tumors that will not affect life expectancy.
- •4. Patients having out of range lab values during screening and before the first dose of study treatment. Out of range lab values are defined as:
- •- Absolute neutrophil count (ANC) <1.0 x 10e9/L
- •- Platelets <75 x 10e9/L
- •- Hemoglobin (Hgb) < 10g/dL
- •- Serum creatinine > 1.5 x ULN or creatinine clearance < 60mL/min using Cockcroft-Gault formula
- •- Total bilirubin > 1.5 x ULN , except for patients with Gilbert syndrome > 3.0 x ULN or direct bilirubin > 1.5 x ULN
- •- Aspartate aminotransferase (AST) > 3 x ULN
- •- Alanine aminotransferase (ALT) > 3 x ULN
- •- Serum electrolytes >= grade 2 despite adequate supplementation.
- •5. Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:
- •- =< 4 weeks for radiation therapy or limited field radiation for palliation within =< 2 weeks prior to the first dose of study treatment.
- •- =< 4 weeks or =< 5 half-lives (whichever is shorter) for chemotherapy or biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other investigational agent.
- •- =< 6 weeks for cytotoxic agents with major delayed toxicities, such as nitrosourea and mitomycin C.
- •- =< 4 weeks for immuno-oncologic therapy, such as CTLA-4, PD-1, or PD-L1 antagonists.
- •6. Patients who have undergone major surgery =< 4 weeks prior to first dose of study treatment or who have not recovered for the surgical procedure.
- •7. Patient previously treated with a HIF2alfa inhibitor.
研究者
相似试验
进行中（未招募）
1 期
A Phase I/Ib study of DFF332 as a single agent and in combination with Everolimus or Immuno-oncology therapies in patients with advanced/relapsed ccRCC and other malignancies with HIF2alpha stabilizing mutations.Advanced, relapsed Clear Cell Renal Cell CarcinomaMedDRA version: 21.0Level: LLTClassification code 10038396Term: Renal carcinoma recurrentSystem Organ Class: 100000004864EUCTR2020-004383-25-ESovartis Farmacéutica, S.A.187
进行中（未招募）
1 期
A Phase I/Ib study of DFF332 as a single agent and in combination with Everolimus or Immuno-oncology therapies in patients with advanced/relapsed ccRCC and other malignancies with HIF2alpha stabilizing mutations.Advanced, relapsed Clear Cell Renal Cell CarcinomaMedDRA version: 21.0Level: LLTClassification code 10038396Term: Renal carcinoma recurrentSystem Organ Class: 100000004864EUCTR2020-004383-25-CZovartis Pharma AG187
进行中（未招募）
1 期
Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.Advanced, relapsed Clear Cell Renal Cell CarcinomaMedDRA version: 21.0Level: LLTClassification code: 10038396Term: Renal carcinoma recurrent Class: 10029104CTIS2024-513379-41-00ovartis Pharma AG150
已完成
1 期
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumorsJPRN-jRCT2080224700ovartis Pharma. K.K.380
招募中
1 期
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and othertypes of cancers of the skin and mucosal membranes in the body.Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)MedDRA version: 20.0Level: PTClassification code: 10040808Term: Skin cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10081431Term: Uveal melanoma Class: 100000004864CTIS2023-509451-14-00ovartis Pharma AG75